Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
Status:
Withdrawn
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To study ex-vivo purging of autologous hematopoietic stem cells that will be used to
support high-dose chemotherapy in patients with chronic myelogenous leukemia (CML). Major
endpoints are neutrophil engraftment and survival.
Secondary Objectives:
1. To evaluate the toxicity of ex-vivo purged autologous cells when used to support
high-dose chemotherapy.
2. To evaluate the rate and duration of cytogenetic remissions achieved with this strategy.
3. To determine the time to platelet recovery to 20,000/mm3.
4. To determine the one-year survival rate.